Talphera
Open
$0.91
Prev. Close
$0.91
High
$0.91
Low
$0.91
Market Snapshot
$37.69M
-2.6
-0.51
12
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
emptyResult
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Recently from Cashu
Talphera's Research Enhances Anticoagulation Strategies in Critical Kidney Care
Talphera Advances Critical Anticoagulation Research for Renal Therapy Talphera, Inc., a specialty pharmaceutical company located in San Mateo, California, is making significant strides in critical car…
Talphera's Innovations in Continuous Renal Replacement Therapy for High-Risk Patients
Talphera Sets the Stage for the Future of Continuous Renal Replacement Therapy Talphera, Inc., a specialty pharmaceutical company based in San Mateo, California, prepares for a significant virtual inv…
Talphera Hosts Virtual Event on Innovative Renal Therapies and Niyad Product Insights
Talphera Prepares for Insightful Discussion on Innovative Renal Therapies Talphera, Inc., a San Mateo-based specialty pharmaceutical company, is set to host a virtual investor and analyst event on Mar…
Talphera Advances NEPHRO-CRRT Study Enrollment Amid Strategic Changes and Industry Focus.
Talphera Makes Significant Progress in NEPHRO-CRRT Study Enrollment Talphera, Inc., a specialist pharmaceutical company, reaches a pivotal milestone in its NEPHRO-CRRT registrational study, having suc…